Impact of genetic polymorphisms in cytomegalovirus glycoprotein b on outcomes in solid-organ transplant recipients with cytomegalovirus disease

Clinical Infectious Diseases

Volumn 49, Issue 8, 2009, Pages 1160-1166

  Manuel, Oriol ^a,b   Åsberg, Anders ^c   Pang, Xiaoli ^b   Rollag, Halvor ^d   Emery, Vincent C ^f   Preiksaitis, Jutta K ^b   Kumar, Deepali ^a   Pescovitz, Mark D ⁱ   Bignamini, Angelo A ^h   Hartmann, Anders ^e   Jardine, Alan G ^g   Humar, Atul ^a,j  

^a Infectious Disease Epidemiology   (United Kingdom)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF LONDON   (United Kingdom)

^d Institute of Microbiology   (United Kingdom)

^e UNIVERSITY OF OSLO   (Norway)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

^h Hyperphar   (Italy)

ⁱ INDIANA UNIVERSITY   (United States)

^j 6 030 Katz Rexall Center for Health Research   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN B; VALGANCICLOVIR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MULTICENTER STUDY; NONHUMAN; ORGAN TRANSPLANTATION; PREVALENCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS LOAD; VIRUS STRAIN;

ADULT; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; ORGAN TRANSPLANTATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; RECURRENCE; SEVERITY OF ILLNESS INDEX; VIRAL ENVELOPE PROTEINS; VIRAL LOAD; VIRULENCE;

EID: 70349906725     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/605633     Document Type: Article

References (32)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med. 2007; 357:2601-2614
2. Meylan PR, Manuel O. Late-onset cytomegalovirus disease in patients with solid organ transplant. Curr Opin Infect Dis 2007;20:412-418 (Pubitemid 47026240)
3. Freeman RB, Paya C, Pescovitz MD, et al; Valganciclovir Solid Organ Transplant Study Group. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 2004;78:1765-1773
4. Lowance D, Neumayer H.H, Legcndre CM, et al; International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999;340:1462-1470
5. Limaye AP, Bakthavatsalam R, Kim. HW, et al. Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis. Transplantation 2006;81:1645-1652 (Pubitemid 43948296)
6. Razonable RR, Rivero A, Rodriguez A, et al. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. J Infect Dis 2001; 184:1461-1464 (Pubitemid 33108862)
7. Emery VC. Viral dynamics during active cytomegalovirus infection and pathology. Intervirology 1999;42:405-411 (Pubitemid 30122077)
8. Nebbia G, Mattes FM, Sabin CA, et al. Differential effects of prednisolone and azathioprine on the development of human cytomegalovirus replication post liver transplantation. Transplantation 2007; 84:605-610 (Pubitemid 47429041)
9. Humar A, Kumar D, Boivin G, Caliendo AM. Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 2002;186:829-833 (Pubitemid 35013436)
10. Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000; 355:2032-2036 (Pubitemid 30339241)
11. Humar A, Gregson D, Caliendo AM, et al. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients. Transplantation 1999; 68: 1305-1311
12. Regoes RR, Bowen EF, Cope AV, et al. Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis. Proc Biol Sei 2006;273:1961-1967
13. Manuel O, Pascual M, Trendelenburg M, Meylan PR. Association between mannose-binding lectin deficiency and cytomegalovirus infection after kidney transplantation. Transplantation 2007; 83:359-362 (Pubitemid 46247871)
14. Sagedal S, Thiel S, Hansen TK, Mollnes TE, Rollag H, Hartmann A. Impact of the complement lectin pathway on cytomegalovirus disease early after kidney transplantation. Nephrol Dial Transplant 2008; 23: 4054-4060
15. Mattes FM, Vargas A, Kopycinski J, et al. Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation. Am J Transplant 2008; 8:990-999
16. La Rosa C, Limaye AP, Krishnan A, Longmate J, Diamond D.J. Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. J Infect Dis 2007; 195:633-714 (Pubitemid 46273036)
17. Gerna G, Lilleri D, Fornara C, et al. Monitoring of human cytomegalovirus-spedfic CD4 and CD8 T-cell immunity in patients receiving solid organ transplantation. Am J Transplant 2006; 6:2356-2364 (Pubitemid 44359421)
18. Scalzo AA, Corbett AJ, Rawlinson WD, Scott GM, Degli-Esposti MA. The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection. Immunol Cell Biol 2007; 85:46-54. (Pubitemid 46067321)
19. Boehme KW, Singh J, Perry ST, Compton T. Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B. J Virol 2004;78:1202-1211 (Pubitemid 38095830)
20. Navarro D, Paz P, Tugizov S, Topp K, La Vail J, Pereira L. Glycoprotein B of human cytomegalovirus promotes virion penetration into cells, transmission of infection from cell to cell, and fusion of infected cells. Virology 1993; 197:143-158 (Pubitemid 23313542)
21. Chou S.W., Dennison K.M. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes. J Infect Dis 1991;163:1229-1234
22. Coaquette A, Bourgeois A, Dirand C, Varin A, Chen W, Herbein G. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. Clin Infect Dis 2004;39:155-161 (Pubitemid 38971482)
23. Humar A, Kumar D, Gilbert C, Boivin G. Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solidorgan-transplant recipients with CMV disease. J Infect Dis 2003; 188: 581-584 (Pubitemid 37011812)
24. Asberg A, Humar A, Rollag H, et al; VICTOR Study Group. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am. J Transplant 2007;7:2106-2113 (Pubitemid 47247057)
25. Humar A, Michaels M; AST ID Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant 2006;6:262-274 (Pubitemid 43382161)
26. Pang X.L., Humar A, Preiksaitis J.K. Concurrent genotyping and quantitation of cytomegalovirus gB genotypes in solid organ transplant recipients using a real-time PCR assay. J Clin Microbiol 2008;46:4004-4010
27. Sarcinella L, Mazzulli T, Willey B, Humar A. Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients. J Clin Virol 2002;24:99-105. (Pubitemid 34016019)
28. Aquino VH, Figueiredo LT. High prevalence of renal transplant recipients infected with more than one cytomegalovirus glycoprotein B genotype. J Med Virol 2000;61:138-142
29. Retière C, Lesimple B, Lepelletier D, Bignon JD, Hallet MM, ImbertMarcille BM. Association of glycoprotein B and immediate early-1 genotypes with human leukocyte antigen alleles in renal transplant recipients with cytomegalovirus infection. Transplantation 2003; 75: 161-165 (Pubitemid 36139715)
30. Manuel O, Pang XL, Humar A, Kumar D, Doucette K, Preiksaitis JK. An assessment of donor to recipient transmission patterns of human cytomegalovirus by analyzing viral genomic variants. J Infect Dis 2009; 199:1621-1628
31. Muheim C, Vogel G, Seydoux C, et al. Determinants of protracted cytomegalovirus infection in solid-organ, transplant patients. Transplantation 2002; 74:226-236 (Pubitemid 34810291)
32. Ishibashi K, Tokumoto T, Tanabe K, et al. Association of the outcome of renal transplantation with antibody response to cytomegalovirus strain-specific glycoprotein H epitopes. Clin Infect Dis 2007;45:60-67 (Pubitemid 46984617)